

# P2Y Receptors Modulate Ion Channel Function through Interactions Involving The C-Terminal Domain

SO YEONG LEE, SAMUEL C. WOLFF, ROBERT A. NICHOLAS, and SCOTT M. O'GRADY

Department of Physiology and Molecular Veterinary Biosciences Graduate Program (S.Y.L.) and Departments of Physiology and Animal Science (S.M.O.), University of Minnesota, St. Paul, Minnesota; and Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (S.C.W., R.A.N.)

Received October 17, 2002; accepted January 3, 2003

This article is available online at <http://molpharm.aspetjournals.org>

## ABSTRACT

Nucleotide stimulation of  $G_q$ -coupled P2Y receptors expressed in *Xenopus laevis* oocytes produces the activation of an endogenous voltage-gated ion channel, previously identified as the transient inward ( $T_{in}$ ) channel. Expression of human P2Y<sub>1</sub>, human P2Y<sub>2</sub>, rat P2Y<sub>6</sub>, human P2Y<sub>11</sub>, or skate P2Y receptors in oocytes resulted in modulation of the voltage dependence and inactivation gating of the channel. Expression of the human P2Y<sub>4</sub> receptor, rat M<sub>1</sub>-muscarinic receptor, and human B<sub>1</sub>-bradykinin receptor did not alter the properties of the  $T_{in}$  channel. Replacement of the C-terminal domain of the human B<sub>1</sub>-bradykinin receptor with the C-terminal domains of either the human P2Y<sub>1</sub> or human P2Y<sub>2</sub> receptor resulted in voltage dependence and inactivation-gating properties, respectively, of the  $T_{in}$  channel that were similar to those elicited by the respective native P2Y receptor. Systematic truncation of the C-termi-

nal region of the human P2Y<sub>1</sub> receptor identified a short region responsible for modulation of the  $T_{in}$  channel. This region contains a conserved sequence motif found in all P2Y receptors that modulates the voltage dependence of the  $T_{in}$  channel. Synthetic 20-mer peptides from the C-terminal domains of human P2Y<sub>1</sub> and P2Y<sub>2</sub> receptors produced a shift in the voltage dependence and slowed inactivation gating, respectively, after injection into oocytes expressing human B<sub>1</sub>-bradykinin or truncated human P2Y<sub>1</sub> receptors. These results indicate that certain P2Y receptors are capable of modulating the voltage sensitivity and inactivation gating of an endogenous oocyte ion channel through interactions involving the C-terminal region of the receptor. Such modulation of ion channel function could also exist in native mammalian cells that express P2Y receptors.

Extracellular nucleotides (ADP, ATP, UDP, and UTP) function as signaling molecules that mediate a variety of biological effects through a family of cell surface receptors known as P2 receptors. This family is divided into two groups: the ionotropic P2X receptors and the metabotropic P2Y receptors (Dubyak and el-Moatassim, 1993; Boarder et al., 1995; Boarder and Hourani, 1998; Ralevic and Burnstock, 1998). Currently, seven mammalian P2X receptors (P2X<sub>1-7</sub>) and eight mammalian P2Y receptors (P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, P2Y<sub>6</sub>, P2Y<sub>11</sub>, P2Y<sub>12</sub>, P2Y<sub>13</sub>, and P2Y<sub>14</sub>) have been cloned and functionally characterized (Ralevic and Burnstock, 1998; von Kugelgen and Wetter, 2000; Communi et al., 2001; Nicholas, 2001; Sak and Webb, 2002). P2X receptors function as non-selective cation channels with inwardly rectifying current-voltage relationships (Dubyak and el-Moatassim, 1993; Ralevic and Burnstock, 1998). Activation of these receptors with ATP or 2-methylthio-ATP (2MeS-ATP) produces membrane depolarization. P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, and P2Y<sub>6</sub> receptors couple

to  $G_{q/11}$  and activate phospholipase C, resulting in increased inositol phosphate-3 formation and mobilization of intracellular  $Ca^{2+}$  (Parr et al., 1994; Communi et al., 1995; Schachter et al., 1996; Lazarowski et al., 2001). The P2Y<sub>11</sub> receptor activates both phospholipase C and adenylyl cyclase (Communi et al., 1997), whereas P2Y<sub>12</sub> and P2Y<sub>13</sub> receptors are coupled solely to  $G_i$  and inhibition of adenylyl cyclase (Daniel et al., 1998; Hollopeter et al., 2001). P2Y<sub>14</sub> receptors are orphan G protein-coupled receptors that are activated by UDP-glucose and couple to the  $G_{i/o}$  class of G proteins (Chambers et al., 2000). The skate (s) P2Y receptor has 61 to 64% sequence similarity to the human (h) P2Y<sub>1</sub> receptor, is coupled to  $G_q$ /phospholipase C, and has a rank order of potency similar to the P2Y<sub>1</sub> receptor (Dranoff et al., 2000).

Previously, we showed that agonist activation of the P2Y<sub>1</sub> receptor expressed in *Xenopus laevis* oocytes stimulated a slowly activating inward current that inactivated within seconds after stimulation (O'Grady et al., 1996). The channel exhibits steady-state inactivation at strong hyperpolarizing potentials. This inward current was identified previously as the transient inward ( $T_{in}$ ) current and was first observed

This work was supported in part by a grant from the Minnesota Applied Ecological Services (project 82) to S.M.O.

**ABBREVIATIONS:** 2MeS, 2-methylthio-;  $T_{in}$ , transient inward; CaCC,  $Ca^{2+}$ -activated  $Cl^-$  channels; CFTR, cystic fibrosis transmembrane conductance regulator; PDZ, PSD-95, Disc-large, and ZO-1; MBS, modified Barth's saline; prefixes: s, skate; h, human; r, rat.

after injection of mRNA from rat brain (Parker et al., 1985) and subsequently observed when cloned 5-hydroxytryptamine-1a and 5-hydroxytryptamine-2c receptors were expressed in oocytes (Ni et al., 1997). The channel is expressed in stage V and VI oocytes but seems to be absent in earlier stages of oocyte maturation. It is reversibly blocked by polyvalent cations including  $\text{Ba}^{2+}$ ,  $\text{Mn}^{2+}$ , and  $\text{La}^{3+}$ .  $T_{\text{in}}$  current activation requires membrane hyperpolarization and an increase in intracellular  $\text{Ca}^{2+}$  (Parker et al., 1985; Ni et al., 1997). Expression of  $\text{G}\alpha_q$  in mature oocytes was found to be sufficient for activation of the  $T_{\text{in}}$  current (Guttridge et al., 1995). The channel responsible for the  $T_{\text{in}}$  current has not been cloned and seems to represent a new family of ion channels that has not been previously characterized.

Interactions between expressed membrane proteins and endogenous ion channels that produce altered properties of these channels have been documented previously. For example, previous studies of  $\text{Ca}^{2+}$ -activated  $\text{Cl}^-$  channels (CaCC) in bovine artery endothelial cells showed that biophysical properties of the channel could be modulated by expression of cystic fibrosis transmembrane conductance regulator (CFTR) (Wei et al., 2001). Stimulation of the cells with forskolin and 3-isobutyl-1-methylxanthine produced activation of CFTR and simultaneously inhibited ATP-dependent activation of endogenous CaCC activity. This effect of CFTR on the regulation of CaCC function was independent of the PDZ domain located at the C terminus of CFTR, but was shown to involve sequences within the R domain. CFTR has also been shown to modulate the function of amiloride-sensitive  $\text{Na}^+$  channels expressed in *X. laevis* oocytes (Boucherot et al., 2001). In this study, the first functional nucleotide-binding domain (NBF1) was proposed to be an interaction site between the two channels because mutations in the NBF1 region of CFTR resulted in a decrease in its ability to inhibit amiloride-sensitive  $\text{Na}^+$  channel activity.

In this study, we examined the effects of native P2Y receptor subtypes on channel function and observed that several members of the P2Y receptor family modified the functional properties of the channel. To address the hypothesis that these receptors modulate the gating and voltage dependence of the  $T_{\text{in}}$  channel through membrane-delimited interactions involving specific structural domains of the receptor, we constructed truncation mutants and chimeric receptors involving the C-terminal regions of  $\text{hP2Y}_1$  and  $\text{hP2Y}_2$  receptors and determined the effects of these mutations on the biophysical properties of the  $T_{\text{in}}$  channel. Our results indicate that the C-terminal domains of these P2Y receptors are involved in regulating voltage dependence or inactivation gating of the  $T_{\text{in}}$  channel. An analysis of C-terminal sequences of P2Y receptors suggests that there are protein-protein interaction domains, distinct from their PDZ-binding motifs, which are involved in the coupling and modulation of channel function.

## Materials and Methods

**Materials.** *X. laevis* frogs were purchased from Xenopus I (Ann Arbor, MI) and maintained in aquaria as suggested by the supplier. Collagenase and gentamicin were obtained from Invitrogen (Carlsbad, CA). 2MeS-ADP and 2MeS-ATP were obtained from Sigma/RBI (Natick, MA). UDP, UTP, carbachol, bradykinin, and isoproterenol were obtained from Sigma (St. Louis, MO). [D-Pen<sup>2</sup>, D-Pen<sup>5</sup>]-enkephalin was obtained from Bachem Biosciences (King of Prussia, PA).

**Construction of Truncated and Chimeric Receptors.** Truncated P2Y receptors were constructed by polymerase chain reaction

using a 3' primer with a stop codon at the desired location and an *XhoI* restriction site to aid in subcloning. Chimeric receptors were generated by overlap-extension polymerase chain reaction (Ho et al., 1989). All receptor constructs were verified by sequencing and were subcloned into pcDNA3.

**Preparation of RNA for Injection.** cRNA was synthesized from linear cDNA encoding either wild-type P2Y receptor or mutants using Megascript (Ambion, Austin, TX).

**Oocyte Isolation and Injection.** Ovarian lobes from adult *X. laevis* frogs were removed from anesthetized animals under sterile condition. The tissue mass was dissociated with collagenase solution (90 mM NaCl, 1 mM KCl, 0.82 mM  $\text{MgSO}_4$ , 10 mM HEPES, pH 7.4, and 250 units/ml collagenase). Stage V and VI oocytes were sorted, defolliculated, and maintained in modified Barth's saline solution (MBS solution: 90 mM NaCl, 2 mM KCl, 0.82 mM  $\text{MgSO}_4$ , 0.74 mM  $\text{CaCl}_2$ , and 10 mM HEPES, pH 7.4, supplemented with 0.05  $\mu\text{g}/\mu\text{l}$  gentamicin) at 19 to 20°C. Oocytes were injected with cRNA transcripts (46 ng/oocyte) using a Nanoject oocyte injection system (Drummond Scientific (Broomall, PA). Control oocytes were injected with 46 nl of sterile water. Oocytes were stored for 2 to 7 days in MBS solution before analysis.

**Peptide Synthesis and Purification.** Peptides of 20 amino acids corresponding to the C-terminal sequence of the  $\text{hP2Y}_1$  receptor (RKASRRSEANLQSKSEDMTL) or the  $\text{hP2Y}_2$  receptor (RRSDRTDMQRIGDVLGSSED) were synthesized by the MicroChemical Facility at the University of Minnesota (St. Paul, MN). Peptides were purified by high-pressure liquid chromatography before injection, and the appropriate amino acid composition was confirmed by amino acid analysis.


**Electrophysiological Measurements.** Electrophysiological measurements were made using the two-electrode voltage-clamp technique at 20°C. Recordings were conducted in  $\text{Cl}^-$ -free MBS solution (90 mM NaMeSO<sub>4</sub>, 2 mM KMeSO<sub>4</sub>, 0.82 mM  $\text{MgSO}_4$ , 0.74 mM calcium gluconate, and 10 mM HEPES, pH 7.4). Electrodes were placed in a separate  $\text{Cl}^-$ -containing MBS solution and connected to the oocyte bathing solution with an agar bridge. Current- and voltage-measuring electrodes were pulled from borosilicate filament glass to resistances between 2 and 5 M $\Omega$  when filled with 0.5 M KCl. Data acquisition and analysis was performed with a Pentium PC using pCLAMP 8 software (Axon Instruments, Inc., Union City, CA).

**Analysis and Statistics.** Statistical significance was determined using Student's *t* test. Statistical significance was accepted at  $p < 0.05$ . Conductance-voltage relationships were analyzed using a Boltzmann function ( $Y = 1/(1 + \exp(V_{50} - X/\text{slope factor}))$ ), where  $V_{50}$  represents the voltage at which the conductance is half-maximal, slope factor represents the relative degree of voltage dependence (steepness of the curve), *Y* represents the normalized conductance,  $G/G_{-140 \text{ mV}}$ , and *X* represents a specific voltage.

## Results and Discussion

We previously reported that 2MeS-ADP stimulation of *X. laevis* oocytes expressing the  $\text{hP2Y}_1$  receptor activated a voltage-dependent current with gating characteristics that were identical with the endogenous  $T_{\text{in}}$  channel in oocytes (O'Grady et al., 1996). The ability to measure these currents was dependent on receptor expression and on the presence of agonist. We followed up on these initial studies and report here that although all  $\text{G}_q$ -coupled P2Y receptors are capable of activating  $T_{\text{in}}$  channel currents in the presence of their cognate agonists, the electrophysiological properties of the channel vary markedly depending on the subtype of the receptor.

**Bradykinin Activation of the  $\text{hB}_1$ -Bradykinin Receptor Elicits  $T_{\text{in}}$  Currents in *X. laevis* Oocytes.** Figure 1A shows representative  $T_{\text{in}}$  current traces recorded from oo-



**Fig. 1.** Voltage dependence of the  $T_{in}$  current elicited by agonist-activated  $G_a$ -coupled receptors expressed in *X. laevis* oocytes. A, representative current traces recorded from oocytes expressing the hB<sub>1</sub>-bradykinin receptor. Oocytes were held at 0 mV and then stepped from -140 mV to +80 mV in 20-mV increments. The data represent peak inward current at each voltage step. The I-V relationship was fit with a Boltzmann function. The reversal potential of hB<sub>1</sub>-bradykinin receptor was determined from the fit and had a value of +13 mV. B, normalized conductance as a function of voltage for the  $T_{in}$  channel activated by hP2Y<sub>1</sub> ( $n = 13$ ), hP2Y<sub>4</sub> ( $n = 9$ ), rM<sub>1</sub>-muscarinic ( $n = 16$ ), and hB<sub>1</sub>-bradykinin ( $n = 13$ ) receptors. C, normalized conductance as a function of voltage for hB<sub>1</sub>-bradykinin ( $n = 13$ ), hP2Y<sub>1</sub> ( $n = 13$ ), hP2Y<sub>11</sub> ( $n = 15$ ), and the sP2Y ( $n = 12$ ) receptors. The  $V_{50}$  values and slope factors for each conductance are listed in Table 1. D, the effects of hP2Y<sub>1</sub> receptor expression levels on the conductance-voltage relationship of the  $T_{in}$  channel; inset: conductance values obtained from oocytes injected with increasing amounts of hP2Y<sub>1</sub> receptor mRNA (nanograms).



To investigate the effect of receptor expression levels on the voltage sensitivity of the  $T_{in}$  channel, we injected increasing amounts of hP2Y<sub>1</sub> receptor mRNA into oocytes and monitored the conductance-voltage relationships after receptor

### Role of the C-Terminal Domain of the hP2Y<sub>2</sub> and rP2Y<sub>6</sub> Receptors in T<sub>in</sub> Channel Inactivation Gating.


Receptor Expressed in Oocytes	Agonist Concentration	Reference	V <sub>50</sub>	Slope Factor
			<i>mV</i>	
hB <sub>1</sub> ( <i>n</i> = 13)	2 $\mu$ M Bradykinin	Simpson et al. (2000)	-43.0	-13.4
rM <sub>1</sub> ( <i>n</i> = 16)	10 $\mu$ M Carbachol	Wood et al. (1999)	-51.8	-16.2
hP2Y <sub>4</sub> ( <i>n</i> = 9)	40 $\mu$ M UTP	Communi et al. (1996)	-53.4	-18.8
hP2Y <sub>1</sub> ( <i>n</i> = 13)	20 $\mu$ M 2MeS-ADP	O'Grady et al. (1996)	-72.5*	-18.5
hP2Y <sub>11</sub> ( <i>n</i> = 15)	80 $\mu$ M 2MeS-ATP	Communi et al. (1999)	-73.5*	-15.6
sP2Y ( <i>n</i> = 12)	20 $\mu$ M 2MeS-ADP	Dranoff et al. (2000)	-76.0*	-17.3
hP2Y <sub>1</sub> 334tr ( <i>n</i> = 9)	20 $\mu$ M 2MeS-ADP	O'Grady et al. (1996)	-50.3	-7.6
hP2Y <sub>1</sub> 342tr ( <i>n</i> = 18)	20 $\mu$ M 2MeS-ADP	O'Grady et al. (1996)	-49.0	-10.8
hP2Y <sub>1</sub> 342tr + Y1 peptide ( <i>n</i> = 8)	20 $\mu$ M 2MeS-ADP	O'Grady et al. (1996)	-72.3*	-13.7
hP2Y <sub>1</sub> 349tr ( <i>n</i> = 9)	20 $\mu$ M 2MeS-ADP	O'Grady et al. (1996)	-56.7	-18.5
hP2Y <sub>1</sub> 360tr ( <i>n</i> = 17)	20 $\mu$ M 2MeS-ADP	O'Grady et al. (1996)	-64.4*	-23.0
hP2Y <sub>1</sub> 369tr ( <i>n</i> = 10)	20 $\mu$ M 2MeS-ADP	O'Grady et al. (1996)	-71.2*	-19.2
hB <sub>1</sub> /Y <sub>1</sub> chimera ( <i>n</i> = 6)	2 $\mu$ M Bradykinin	Simpson et al. (2000)	-66.3*	-15.5
hB <sub>1</sub> + Y1 peptide ( <i>n</i> = 7)	2 $\mu$ M Bradykinin	Simpson et al. (2000)	-68.0*	-12.9

\* Value was significantly different from the hB<sub>1</sub>-bradykinin receptor value ( $p < 0.05$ ).


gating of the  $T_{in}$  channel depending on which P2Y receptor was responsible for activating the current. Thus, whereas the current elicited by the hP2Y<sub>1</sub> receptor was almost completely inactivated within 3 s of the hyperpolarizing pulse, the current elicited by either the hP2Y<sub>2</sub> (stimulated with 40  $\mu$ M

UTP) or the rP2Y<sub>6</sub> receptor (stimulated with 40  $\mu$ M UDP) showed significantly slower inactivation. (Fig. 3A). As observed with the voltage gating of the channel, the time course of inactivation was dependent on the identity of the C-terminal domain of the receptor. Thus, the inactivation time


A




B



C




D



**Fig. 2.** Effect of C-terminal truncation on the conductance-voltage relationship. A, normalized conductance as a function of voltage for  $T_{in}$  currents elicited by activated hB<sub>1</sub>-bradykinin ( $n = 13$ ), hP2Y<sub>1</sub> ( $n = 13$ ), and hB<sub>1</sub>/Y<sub>1</sub> chimeric ( $n = 6$ ) receptors. B, location of truncation mutations introduced into the hP2Y<sub>1</sub> receptor. The last four amino acids, DTSL, represent a consensus class 1 PDZ-binding motif. C, normalized conductance as a function of voltage for  $T_{in}$  currents elicited by activated hB<sub>1</sub>-bradykinin ( $n = 13$ ), hP2Y<sub>1</sub> ( $n = 13$ ), hP2Y<sub>1</sub>360tr ( $n = 17$ ), and hP2Y<sub>1</sub>369tr ( $n = 10$ ) receptors. D, normalized conductance as a function of voltage for  $T_{in}$  currents elicited by activated hP2Y<sub>1</sub> ( $n = 13$ ), hP2Y<sub>1</sub>334tr ( $n = 9$ ), hP2Y<sub>1</sub>342tr ( $n = 18$ ), and hP2Y<sub>1</sub>349tr ( $n = 9$ ) receptors. The  $V_{50}$  values and slope factors for each conductance are listed in Table 1.

courses of the hP2Y<sub>1</sub> receptor containing the hP2Y<sub>2</sub> C-terminal domain (hY<sub>1</sub>/Y<sub>2</sub> chimera) (Fig. 3A) or the hB<sub>1</sub>-bradykinin receptor containing the hP2Y<sub>2</sub> C-terminal domain (hB<sub>1</sub>/Y<sub>2</sub>) (Fig. 3B) were identical with that of the wild-type hP2Y<sub>2</sub> receptor (Fig. 3A).

Figure 3C shows the ratio of the current amplitude at the end of the voltage pulse (−140 mV, 3.8 s) to the maximum inward current elicited by a series of activated receptors. As suggested by the current traces in Fig. 3, A and B, the ratio



**Fig. 3.** Inactivation gating of receptor-activated T<sub>in</sub> currents. **A**, representative traces of the T<sub>in</sub> conductance elicited by activated hP2Y<sub>1</sub>, rP2Y<sub>6</sub>, hP2Y<sub>2</sub>, and hY<sub>1</sub>/Y<sub>2</sub> chimeric receptors. T<sub>in</sub> channels were monitored for 5 s in the presence of the appropriate receptor agonist. UTP (40 μM) and UDP (40 μM) were used to stimulate the hP2Y<sub>2</sub> and rP2Y<sub>6</sub> receptors, respectively (Parr et al., 1994; Communi and Boeynaems, 1997). 2MeS-ADP (20 μM) was used to activate the hP2Y<sub>1</sub> receptor and hY<sub>1</sub>/Y<sub>2</sub> chimeric receptors. **B**, representative traces of currents elicited by agonist-activated hB<sub>1</sub>-bradykinin and hB<sub>1</sub>/Y<sub>1</sub>, and hB<sub>1</sub>/Y<sub>2</sub> chimeric receptors after step hyperpolarization to −140 mV. **C**, I<sub>final</sub>/I<sub>max</sub> is the current amplitude at the end of the voltage pulse (as indicated by the open arrows in parts A and B) divided by the maximum inward current and represents the degree of T<sub>in</sub> channel inactivation gating. This ratio was significantly increased in hP2Y<sub>2</sub> (*n* = 10), rP2Y<sub>6</sub> (*n* = 11), hY<sub>1</sub>/Y<sub>2</sub> (*n* = 7), hY<sub>2</sub>/Y<sub>1</sub> (*n* = 7), and hB<sub>1</sub>/Y<sub>2</sub> (*n* = 7) chimeric receptors (*p* < 0.05).

derived from the hP2Y<sub>1</sub> receptor-activated currents was near zero. In contrast, the ratio was nearly 0.8 for the current elicited by the hP2Y<sub>2</sub> receptor, rP2Y<sub>6</sub> receptor, and the hY<sub>1</sub>/Y<sub>2</sub> chimera, indicating slow inactivation. Although the ratio of the current elicited by the hY<sub>2</sub>/Y<sub>1</sub> chimera was significantly decreased compared with wild-type hP2Y<sub>2</sub> receptor, it was still significantly greater than that observed after hP2Y<sub>1</sub> and hP2Y<sub>4</sub> receptor activation.

**C-Terminal Sequence Comparisons of P2Y Receptors.** Figure 4 compares the C-terminal sequences of all five of the G<sub>q</sub>-coupled P2Y receptors (P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, P2Y<sub>6</sub>, and P2Y<sub>11</sub>). Within the C-terminal domains of the hP2Y<sub>1</sub>, hP2Y<sub>11</sub>, and sP2Y receptor, all of which modulate the voltage activation of the T<sub>in</sub> channel, a common sequence motif was observed (RRSE—**QXK**/RSE) (bold letters identify conserved amino acids between P<sub>2</sub>Y receptor subtypes). Importantly, this sequence motif falls within the narrow region of the hP2Y<sub>1</sub> receptor C-terminal domain shown to be involved in modulating voltage sensitivity (Fig. 2). Likewise, a different conserved sequence motif (**QRXG**/R) was observed in the C-terminal domains of the hP2Y<sub>2</sub> and rP2Y<sub>6</sub> receptor, both of which modulate T<sub>in</sub> channel inactivation. This motif is not present in the other P2Y receptors.


**Effects of Y1 and Y2 C-Terminal Peptides on the Conductance-Voltage Relationships and Inactivation Gating of the T<sub>in</sub> Channel.** To examine whether the unique sequence motif present in the C-terminal region of the hP2Y<sub>1</sub> receptor was able to modulate the conductance-voltage relationship of the T<sub>in</sub> current, a synthetic peptide (Y1 peptide) (boxed region in Fig. 4) was injected into hP2Y<sub>1</sub>342tr-expressing oocytes (final concentration ≈ 500 nM), and the conductance-voltage relationship of the T<sub>in</sub> channel was determined (Fig. 5A). The V<sub>50</sub> value of the conductance elicited by the hP2Y<sub>1</sub>342tr receptor with 500 nM Y1 peptide (−72.3 mV) was significantly different from the value elicited by the hP2Y<sub>1</sub>342tr receptor alone (V<sub>50</sub> = −49.0 mV) and similar to that elicited by the wild-type hP2Y<sub>1</sub> receptor (V<sub>50</sub> = −72.5 mV) (Table 1). The Y1 peptide produced a similar negative shift in the V<sub>50</sub> value (−68.0 mV) in oocytes expressing the hB<sub>1</sub>-bradykinin receptor compared with the hB<sub>1</sub>-bradykinin receptor alone (−43.0 mV) (Fig. 5B).

To examine whether the proposed sequence motif present in the C-terminal region of the hP2Y<sub>2</sub> receptor was able to modulate the inactivation gating of the T<sub>in</sub> current, a 20 amino acid peptide (Y2 peptide) (boxed region in Fig. 4) from the C terminus of the hP2Y<sub>2</sub> receptor encompassing this

hP2Y1	RRRLSR-ATRKASRRSEANLQSKSEDMTINILPEPKQNGDSTL
hP2Y11	LLYMAA-VPSLGCCCRHCPGYRDSWNPEDAKSTGQALPLNATAAPK <b>SE</b> Q <b>SR</b> ELSQ
Skate	RRRFTNAASRFMT <b>RR</b> SELSMQ <b>FR</b> SEDSPLQPVSNISQNGDSTL
hP2Y4	RRQL-RQLCGGG-KPQP-RTAASSLALVSLPEDSSCRWAATPDQSSCSTPRADRL
hP2Y2	RRRLGI <b>RR</b> SDRTDM <b>ORIG</b> DVLGSSSEDFRRTTESTPAGESNTKDRL
hP2Y6	RRRPHELLQKLTAQW <b>QRQR</b>
rP2Y6	RRQPHDLLQKLTAQW <b>QRQRV</b>
mP2Y6	RRQPHDLLQRLTAQW <b>QRQRV</b>

**Fig. 4.** C-terminal sequence comparisons between P2Y receptors. The underlined and bolded amino acids represent potential sequences involved in protein-protein interactions with the T<sub>in</sub> channel. hP2Y<sub>1</sub>, hP2Y<sub>11</sub>, and sP2Y receptors modulate voltage dependence, whereas hP2Y<sub>2</sub> and rP2Y<sub>6</sub> receptors modulate inactivation gating. A similar sequence motif affecting inactivation gating of the channel is present in the mouse (m) P2Y<sub>6</sub> receptor. The boxed amino acids in the hP2Y<sub>1</sub> and hP2Y<sub>2</sub> receptor sequences indicate the peptide sequences used for experiments shown in Fig. 5.





**Fig. 5.** Effect of Y1 and Y2 C-terminal peptides on the conductance-voltage relationship and inactivation gating of  $T_{\text{in}}$  currents. **A**, normalized conductance as a function of voltage of  $T_{\text{in}}$  currents elicited by the agonist-activated hP2Y<sub>1</sub>342tr receptor (Y<sub>1</sub>tr;  $n = 18$ ), hP2Y<sub>1</sub>342tr receptor with 500 nM Y1 peptide ( $n = 8$ ), and hP2Y<sub>1</sub> receptor ( $n = 13$ ). **B**, normalized conductance as a function of voltage of  $T_{\text{in}}$  currents elicited by the hB<sub>1</sub>-bradykinin receptor ( $n = 13$ ), the hB<sub>1</sub>-bradykinin receptor with 500 nM Y1 peptide ( $n = 7$ ), and the hP2Y<sub>1</sub> receptor ( $n = 13$ ). **C**,  $I_{\text{final}}/I_{\text{max}}$  ratios of the  $T_{\text{in}}$  current elicited by the indicated receptors were calculated as described in the legend to Fig. 3. The ratios were significantly increased for the hP2Y<sub>1</sub>342tr receptor with 500 nM Y2 peptide ( $n = 6$ ), the hB<sub>1</sub>-bradykinin receptor with 500 nM Y2 peptide ( $n = 6$ ), and the hP2Y<sub>2</sub> receptor ( $n = 10$ ) ( $p < 0.05$ ).

sequence was injected into hP2Y<sub>1</sub>342tr- or hB<sub>1</sub>-bradykinin receptor-injected oocytes (final concentration  $\approx 500$  nM), and the inactivation gating of the  $T_{\text{in}}$  channel was determined. Figure 5C shows the ratio of the current amplitude at the end of the voltage pulse ( $-140$  mV) to the maximum inward current observed after activation. The ratio obtained from the hP2Y<sub>1</sub>342tr and hB<sub>1</sub>-bradykinin receptor-activated currents was nearly zero, whereas the ratio for the current elicited by hP2Y<sub>1</sub>342tr or hB<sub>1</sub>-bradykinin receptor with Y2 peptide was significantly increased (although not to the same level) compared with hP2Y<sub>1</sub>342tr and hB<sub>1</sub>-bradykinin receptor-activated currents alone or hP2Y<sub>1</sub>342tr and hB<sub>1</sub>-bradykinin receptor-activated currents with Y1 peptide.

Taken together, these data strongly suggest that the C termini of the hP2Y<sub>1</sub> and hP2Y<sub>2</sub> receptors interact in some manner with the  $T_{\text{in}}$  channel to modulate its biophysical properties. We hypothesize that two sequence motifs, RRSE—QXK/RSE and QRXG/R, located in the C-termini of P2Y receptors, are important protein-protein interaction sites between P2Y receptors and the  $T_{\text{in}}$  channel, or alternatively an intermediate adapter protein. The presence of multiple protein-protein interaction domains within the C-terminal region of P2Y receptors suggests that these receptors can couple to a variety of membrane-associated proteins and potentially influence their function, independent of G-protein activation. Future studies directed toward identifying additional interacting protein partners should provide better insight into the role of protein-protein interactions in P2Y receptor signaling.

#### Acknowledgments

We thank Drs. Linda Boland and Ken Harden for helpful comments and suggestions.

#### References

- Boarder MR and Hourani SM (1998) The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. *Trends Pharmacol Sci* **19**:99–107.
- Boarder MR, Weisman GA, Turner JT, and Wilkinson GF (1995) G protein-coupled P2 purinergic receptors: from molecular biology to functional responses. *Trends Pharmacol Sci* **16**:133–139.
- Boucherot A, Schreiber R, and Kunzelmann K (2001) Role of CFTR's PDZ1-binding domain, NBF1 and Cl(–) conductance in inhibition of epithelial  $\text{Na}^+$  channels in *Xenopus* oocytes. *Biochim Biophys Acta* **1515**:64–71.
- Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, Zhu Y, McLaughlin MM, Murdock P, McMillan L, et al. (2000) A G protein-coupled receptor for UDP-glucose. *J Biol Chem* **275**:10767–10771.
- Communi D and Boeynaems JM (1997) Receptors responsive to extracellular pyrimidine nucleotides. *Trends Pharmacol Sci* **18**:83–86.
- Communi D, Gonzalez NS, Detheux M, Brezillon S, Lannoy V, Parmentier M, and Boeynaems JM (2001) Identification of a novel human ADP receptor coupled to  $G_i$ . *J Biol Chem* **276**:41479–41485.
- Communi D, Govaerts C, Parmentier M, and Boeynaems JM (1997) Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. *J Biol Chem* **272**:31969–31973.
- Communi D, Motte S, Boeynaems JM, and Piroton S (1996) Pharmacological characterization of the human P2Y<sub>4</sub> receptor. *Eur J Pharmacol* **317**:383–389.
- Communi D, Piroton S, Parmentier M, and Boeynaems JM (1995) Cloning and functional expression of a human uridine nucleotide receptor. *J Biol Chem* **270**:30849–30852.
- Communi D, Robaye B, and Boeynaems JM (1999) Pharmacological characterization of the human P2Y<sub>11</sub> receptor. *Br J Pharmacol* **128**:1199–1206.
- Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, and Kunapuli SP (1998) Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. *J Biol Chem* **273**:2024–2029.
- Dranoff JA, O'Neill AF, Franco AM, Cai SY, Connolly GC, Ballatori N, Boyer JL, and Nathanson MH (2000) A primitive ATP receptor from the little skate *Raja erinacea*. *J Biol Chem* **275**:30701–30706.
- Dubyak GR and el-Moatassim C (1993) Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. *Am J Physiol* **265**:C577–C606.
- Guttridge KL, Smith LD, and Miledi R (1995) *Xenopus*  $G_q$   $\alpha$  subunit activates the phosphatidylinositol pathway in *Xenopus* oocytes but does not consistently induce oocyte maturation. *Proc Natl Acad Sci USA* **92**:1297–1301.
- Ho SN, Hunt HD, Horton RM, Pullen JK, and Pease LR (1989) Site-directed mu-

- tagenesis by overlap extension using the polymerase chain reaction. *Gene* **77**:51–59.
- Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurdén P, Nurdén A, Julius D, et al. (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. *Nature (Lond)* **409**:202–207.
- Lazarowski ER, Rochelle LG, O'Neal WK, Ribeiro CM, Grubb BR, Zhang V, Harden TK, and Boucher RC (2001) Cloning and functional characterization of two murine uridine nucleotide receptors reveal a potential target for correcting ion transport deficiency in cystic fibrosis gallbladder. *J Pharmacol Exp Ther* **297**:43–49.
- Ni YG, Panicker MM, and Miledi R (1997) Efficient coupling of 5-HT<sub>1a</sub> receptors to the phospholipase C pathway in *Xenopus* oocytes. *Brain Res Mol Brain Res* **51**:115–122.
- Nicholas RA (2001) Identification of the P2Y<sub>12</sub> receptor: a novel member of the P2Y family of receptors activated by extracellular nucleotides. *Mol Pharmacol* **60**:416–420.
- O'Grady SM, Elmquist E, Filtz TM, Nicholas RA, and Harden TK (1996) A guanine nucleotide-independent inwardly rectifying cation permeability is associated with P2Y<sub>1</sub> receptor expression in *Xenopus* oocytes. *J Biol Chem* **271**:29080–29087.
- Parker I, Gundersen CB, and Miledi R (1985) A transient inward current elicited by hyperpolarization during serotonin activation in *Xenopus* oocytes. *Proc R Soc Lond B Biol Sci* **223**:279–292.
- Parr CE, Sullivan DM, Paradiso AM, Lazarowski ER, Burch LH, Olsen JC, Erb L, Weisman GA, Boucher RC, and Turner JT (1994) Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. *Proc Natl Acad Sci USA* **91**:3275–3279.
- Ralevic V and Burnstock G (1998) Receptors for purines and pyrimidines. *Pharmacol Rev* **50**:413–492.
- Sak K and Webb TE (2002) A retrospective of recombinant P2Y receptor subtypes and their pharmacology. *Arch Biochem Biophys* **397**:131–136.
- Schachter JB, Li Q, Boyer JL, Nicholas RA, and Harden TK (1996) Second messenger cascade specificity and pharmacological selectivity of the human P2Y<sub>1</sub>-purinoceptor. *Br J Pharmacol* **118**:167–173.
- Simpson PB, Woollacott AJ, Hill RG, and Seabrook GR (2000) Functional characterization of bradykinin analogues on recombinant human bradykinin B<sub>1</sub> and B<sub>2</sub> receptors. *Eur J Pharmacol* **392**:1–9.
- von Kugelgen I and Wetter A (2000) Molecular pharmacology of P2Y-receptors. *Naunyn Schmiedeberg's Arch Pharmacol* **362**:310–323.
- Wei L, Vankeerberghen A, Cuppens H, Cassiman JJ, Droogmans G, and Nilius B (2001) The C-terminal part of the R-domain, but not the PDZ binding motif, of CFTR is involved in interaction with Ca<sup>2+</sup>-activated Cl<sup>−</sup> channels. *Pfluegers Arch Eur J Physiol* **442**:280–285.
- Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, and Middlemiss DN (1999) Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM<sub>1</sub>, hM<sub>2</sub>, hM<sub>3</sub>, hM<sub>4</sub>, and hM<sub>5</sub> using microphysiology. *Br J Pharmacol* **126**:1620–1624.

---

**Address correspondence to:** Dr. Scott M. O'Grady, Departments of Physiology and Animal Science, University of Minnesota, 495 Animal Science/Veterinary Medicine Building, 1988 Fitch Avenue, St. Paul, MN, 55108. E-mail: ogrady001@umn.edu

---